Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
67%
Ph phase_2
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Withdrawn2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 42 (66.7%)

Trials by Status

completed133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_4

Spironolactone for Hidradenitis Suppurativa

NCT04100083
withdrawnphase_4

Non-Responsive Diabetic Macular Edema and Spironolactone

NCT04853355
completedphase_2

Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

NCT03744767

Clinical Trials (3)

Showing 3 of 3 trials
NCT04100083Phase 4

Spironolactone for Hidradenitis Suppurativa

Withdrawn
NCT04853355Phase 4

Non-Responsive Diabetic Macular Edema and Spironolactone

Withdrawn
NCT03744767Phase 2

Adjuvant Anti-Mineralocorticoid-Receptor Treatment in Anti-VEGF Refractory Neovascular Age-Related Macular Degeneration

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3